Hikma Pharmaceuticals Share Discussion Threads

[bantam175] 23/5/2018 14:44

It's (hopefully) just the usual Summer slowtime when lots of stuff goes down (all buyers at the beach).

[vas007] 23/5/2018 13:12

Bantam 175 what is going on with this shares ?

[bantam175] 22/5/2018 12:58

Stuff them too.

[r ball] 22/5/2018 06:29

Is it not Barclay's clients?

[bantam175] 21/5/2018 18:08

Barclays seem to have a big short outstanding. Stuff 'em.

[r ball] 18/5/2018 15:58

Give the run up to the trading statement I view a positive finish today as encouraging. No need to sell and every reason to add. Suspect a few upgrades are around the corner.

[investordave] 18/5/2018 14:49

I've just filtered the chinaman. Got tired of his constant repetition. Good stories don't need to be broadcast every hour or so.

[broadwood] 18/5/2018 14:43

LONDON (Alliance News) - FTSE 250-listed Hikma Pharmaceuticals PLC said on Friday the first four months of 2018 brought an "encouraging" start to the year.


The Injectables business saw good demand for its marketed products in Europe, and new launches drive revenue growth in the Middle East and North Africa. In the US the business has found itself able to meet increased demand with new product launches in the year to date.

Hikma expects Injectables revenue to be within the range of USD750 million to USD800 million for 2018, and the operating margin to be at the low to mid 30s. Injectables revenue for 2017 was USD776 million.

The group's Generics business saw a good start to the year despite the US market remaining tough, Hikma said. The segment is on track to consolidate its manufacturing and distribution facilities in the second half of the year, and the repeat clinical endpoint study for Advair Diskus is proceeding as planned.

Revenue from Generics is forecast to be in the range of USD550 million to USD600 million, and the operating margin in the low single digits. Generic revenue for 2017 was USD615 million

Finally, Hikma said it has seen sales growth and new launches for its Branded division, but expects its performance to be more weighted towards the second half of 2018. Revenue growth for the full year is expected to be in the mid-single digits on a constant currency basis.

For 2017, the Branded unit reported revenue of USD536 million.

"The year is off to an encouraging start. In the first four months, our Injectables, Generics and Branded businesses are benefiting from our broad product portfolio and recent product launches. Our efforts to reduce costs across the group are on track and we continue to focus on enhancing and investing in our pipeline. Our cash position remains very healthy and our balance sheet is strong. Altogether, these factors reinforce our positive outlook for the Group and enable us to reiterate our guidance for the full year," said Chief Executive Officer Siggi Olafsson

[r ball] 17/5/2018 08:44

Share price movement triggered by genetics news? Has there been a clamp down on Indian competitors?

[broadwood] 16/5/2018 14:23

Continuing progress on recent rec.

[broadwood] 08/5/2018 09:03

Maybe some of the takeover activity in the sector is spilling over here.

[gerrym two] 02/5/2018 18:30

Nice and steady before it heads to £14 IMO

[karateboy] 01/5/2018 22:37

2000p is achievable after FDA approval is obtained in 2019. I am hoping 2400p by end of 2019.

[bantam175] 30/4/2018 11:10

Shorters back on board again now. Nothing personal but here's hoping they get their fingers burnt.

Back to 2000p and the ftse 100 by end of year would be nice.

[karateboy] 28/4/2018 21:29

SP is consolidating very well. I wounder if next stop will be £15.

[r ball] 24/4/2018 22:58

Buying op. Sentiment change and with ex Teva guy in charge....well

[r ball] 23/4/2018 20:46

Meant Clinigen

[r ball] 23/4/2018 20:45

Doubt it or clingier would have risen too. This. was announced on Friday and the shortage was flagged in July 2017. The FDA website is worth looking at

[broadwood] 23/4/2018 19:49

Strong rise today could be down to this.

Hikma Subsidiary West-Ward Launches Dexrazoxane For Injection for heart problems.

[r ball] 20/4/2018 18:41

Upgrade today...

[broadwood] 20/4/2018 09:00

M&A activity rife in the sector. Could this be next?

[isstaaz] 19/4/2018 12:42

Expected the results to be better than this. Nothing disastrous though. Actually they're not bad considering.

[gerrym two] 12/4/2018 20:31

Back to 1250 territory tomorrow but this might spike even higher....Shire speculation etc could move the sector IMO

[r ball] 12/4/2018 20:12

Intraday drops are fading towards the close.